Endometrial Cancer | Clinical

Racial Disparities Persist Among Women With Endometrial Cancers in Equal-Access Healthcare Systems

October 14, 2021

Despite researchers compiling data from an equal-access system and adjusting for age, diagnosis period, tumor stage, tumor histology/grade, and whether the patient had adjuvant treatment, the overall survival disparity between Black and White women with endometrial cancer persisted.

FDA Accepts sBLA for Pembrolizumab Monotherapy for Endometrial Cancer

August 10, 2021

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial Cancer

July 22, 2021

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.